主要指标是总生存期，次要指标包括无进展生存期(PFS)和客观反应率(ORR)。
The primary endpoint was overall survival, and secondary endpoints included PFS and objective response rate (ORR).
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
应用推荐